American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • Industry

Express Scripts releases 2016 Drug Trend Report

American Pharmacy News Reports | Jun 13, 2017
Drug Channels also wrote about the year-over-year changes in drug spending.

Express Scripts has released its 2016 Drug Trend Report for the commercial market. Read More »

SCOTUS ruling in Sandoz v. Amgen will speed biosimilars to market, could save U.S. consumers billions

LocalLabs News Service | Jun 12, 2017

The U.S. Supreme Court issued a 9-0 ruling today that will have the effect of speeding the process for biosimilars going to market. Read More »

Pfizer furthers partnership for affordable contraception in developing countries

Carol Ostrow | Jun 10, 2017
The all-in-one injection was distributed to 20 developing nations by the end of 2016.

Mutual recommitment to a partnership between Pfizer and two U.S. foundations has successfully ensured continued access to Pfizer’s Sayana Press contraceptive for women in the world’s poorest nations. Read More »

AstraZeneca sells U.S. and Canada commercialization rights for Zoladex

American Pharmacy News Reports | Jun 9, 2017
Zoladex, an injectable luteinizing hormone-releasing hormone agonist, was first approved in the United States and Canada in 1989.

AstraZeneca and TerSera Therapeutics LLC (TerSera) have entered a agreement that gives TerSera the commercial rights to Zoladex in the United States and Canada. Read More »

Endo Pharmaceuticals recalls batch of Edex injection drugs

American Pharmacy News Reports | Jun 6, 2017
Endo noted that the U.S. Food and Drug Administration is aware of the recall.

Endo International plc recently announced that one of its operating companies, Endo Pharmaceuticals Inc. based in Malvern, Pennsylvania, is voluntarily recalling one lot of Edex (alprostadil) for injection because the company detected a defect in the crimp caps used in the manufacture of the subject product lot. Read More »

DelMar Pharmaceuticals hosts Key Opinion Leader forum

American Pharmacy News Reports | Jun 6, 2017
GBM is the most common and most lethal form of brain cancer.

DelMar Pharmaceuticals recently hosted a Key Opinion Leader forum at the Lotte New York Palace Hotel in New York City, highlighting its novel treatment for patients suffering from glioblastoma multiforme. Read More »

Sandoz HACk finalists present ideas to panel of judges

American Pharmacy News Reports | Jun 6, 2017
Sandoz asked participants to use mobile technology to better connect people with the health care industry.

Six finalists of the Sandoz HACk presented their ideals to a panel of judges at WIRE Health in London. Read More »

CVS Health report highlights health care needs of an aging population

Mark Iandolo | Jun 5, 2017
Almost a fourth of baby boomers are expected to live past the age of 90.

CVS Health recently released a report highlighting the health care needs of an aging population, noting that Americans are living longer than ever before. Read More »

Protagonist Therapeutics, Janssen Biotech to share PTG-200 rights

American Pharmacy News Reports | Jun 4, 2017
Janssen and Protagonist will be co-funding the development of the antagonist through Phase 2.

Protagonist Therapeutics Inc., announced May 30 that they have formed a worldwide license and collaboration with Janssen Biotech Inc. Read More »

Innovus Pharmaceuticals signs license and distribution agreement with Luminarie

American Pharmacy News Reports | Jun 4, 2017
Female Sexual Dysfunction is estimated to affect 43 percent of women in the U.S. between 18 and 59.

Innovus Pharmaceuticals Inc. is signing an exclusive license and distribution agreement for commercialization of Zestra and Zestra Glide with Luminarie Pty Ltd. throughout Australia, New Zealand and the Philippines. Read More »

Sierra Oncology receives patent for Chk1 inhibitor

American Pharmacy News Reports | Jun 4, 2017
The patent that Sierra has been granted will provide the company with coverage until 2033.

Sierra Oncology has been granted a selection patent for its Chk1 inhibitor, SRA737 by the U.S. Patent and Trademark Office. Read More »

Technavio projects explosive growth for pharmaceutical packaging market

Tabitha Fleming | Jun 4, 2017
The market for parenteral containers -- containers that include vials, injections, ampoules and pre-filled syringes -- is expected to grow.

According to the Technavio’s latest market study, the North American pharmaceutical packaging market is expected to grow through 2021. Read More »

Direct Relief teams with Pfizer in response to opioid epidemic

LocalLabs News Service | Jun 2, 2017
Direct Relief has already delivered 45,000 doses of life-saving Naloxone to communities hit hardest by the opiod epidemic.

Direct Relief is working with Pfizer to provide up to a million doses of life-saving Naloxone to community health centers, free clinics, public health departments and other non-profits nationwide in response to the opioid epidemic. Read More »

ScriptSave partners with Physicians Mutual

American Pharmacy News Reports | Jun 2, 2017
ScriptSave focuses on solutions for health care and prescription coverage gaps.

ScriptSave recently announced that it has partnered with Physicians Mutual to provide discounts on prescription medication to Physicians Mutual customers through its ScriptSave WellRx program. Read More »

Hematogenix included as Merck & Co. lab for FDA-approved PD-L1 companion

American Pharmacy News Reports | Jun 2, 2017
Hematogenix is a CAP/CLIA-certified laboratory.

Hematogenix Laboratory Services, a company that provides integrated pathology services for drug development, recently announced that that Merck & Co. Inc. has included it as one of the national reference laboratories for U.S. Food and Drug Administration (FDA)-approved PD-L1 companion diagnostic assay PD-L1 IHC 22C3 pharmDx for Keytruda. Read More »

Otsuka earns licensing rights in Japan for Teva's migraine drug

American Pharmacy News Reports | May 31, 2017
Preliminary results for fremanezumab in Phase IIb studies for both chronic and episodic migraines have been promising.

Otsuka Pharmaceutical has entered into a licensing agreement that gives it exclusive rights to develop and commercialize Teva Pharmaceutical Industries' migraine prevention drug fremanezumab in Japan. Read More »

Allergan completes $2.9 billion acquisition of LifeCell Corp.

American Pharmacy News Reports | May 31, 2017
Allergan acquired LifeCell's commercial portfolio, as well as its New-Jersey-based manufacturing capabilities and its R&D operations.

Allergan PLC, a global biopharmaceutical company, recently concluded its $2.9 billion acquisition of LifeCell Corp., a business that develops regenerative medicine. Read More »

Janssen Human Microbiome Institute enters new partnerships

American Pharmacy News Reports | May 31, 2017
The collaborations and investments will create critical new insights to address metabolic disorders.

Janssen Research & Development LLC has identified new partnerships through the company’s Janssen Human Microbiome Institute, a program that develops microbial products through innovation and discovery. Read More »

Electronic prescribing company DrFirst acquires VisibilityRx

American Pharmacy News Reports | May 30, 2017
With the acquisition, the 60,000 physician clients that use DrFirst can now more easily identify and refer patients to new clinical trials.

DrFirst, an electronic prescribing company, has acquired VisibilityRx, a provider of clinical trial recruitment services to life sciences, clinical research organizations and pharmacies. Read More »

Personal Genome Diagnostics receives contract from National Cancer Institute

American Pharmacy News Reports | May 27, 2017
The contract gives the company an opportunity to work with various pharmaceutical partners to develop the MutatorDETECT assay.

Personal Genome Diagnostics Inc. has received a National Cancer Institute contract to develop a novel diagnostic for helping identify patients who are most likely to benefit from cancer drugs called checkpoint inhibitors. Read More »

  • «
  • 1
  • 2
  • ...
  • 16
  • 17
  • 18 (current)
  • 19
  • 20
  • ...
  • 31
  • 32
  • »
Trending

Shaun Noorian, CEO of Empower Pharmacy

Empower Pharmacy challenges Eli Lilly tirzepatide patent before U.S. Patent Trial and Appeal Board

Sally Greenberg, JD, Chief Executive Officer, National Consumers League

National Consumers League announces poll showing support for 340B drug pricing reform

Danea Horn, Researcher, University of California

Researcher on 340B: Physicians 'select patients who require more intensive pharmaceutical treatments after joining the 340B program'

David Balto, Former Policy Director at the Federal Trade Commission

Former FTC director on 340B program: ‘Drug discounts are being captured by corporate hospital systems'

Mary Holland, CEO of CHD

Poll finds majority want pharma accountable for vaccine injuries

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up